Titre
Suivi endocrinologique des adolescents transgenres « L'étude T-ADO »
Type
mémoire de master/maîtrise/licence
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Auteur(s)
BEHARRY, B.
Auteure/Auteur
Directrices/directeurs
BUSIAH, K.
Directeur⸱rice
Liens vers les personnes
Liens vers les unités
Faculté
Université de Lausanne, Faculté de biologie et médecine
Statut éditorial
Accepté
Date de publication
2024
Nombre de pages
58
Langue
français
Résumé
Introduction : Gender Dysphoria (GD) refers to the feeling of discomfort or distress associated with gender incongruence (GI). There are international recommendations to provide the best care for those patients. The aims of the hormonal treatment is to align secondary physical sexual characteristics with the patient's gender identity. Firstly, we have the puberty blockers GnRH agonists (GnRHa) that suppress sex hormone production. Secondly gender-affirming hormones (testosterone or estradiol) help to align the desired physical sex characteristics to the patients’ gender identity.
Objective : Primary objective is to evaluate adequacy between Gender Dysphoria/Gender Incongruence Guidelines of the Endocrine Society and practice at the CHUV. Secondary objective is to describe anthropometric and hormonal parameters in Female to male (FtM) and Male to Female (MtF) starting GnRHa and in FtM starting testosterone.
Design : Observational, prospective and retrospective study
Intervention(s) : Puberty suppression treatment with GnRHa in FtM and in MtF patients. Gender-affirming hormone therapy (GAHT) with testosterone (associated or not with GnRHa) in FtM.
Patients : 2 MtF (both under only GnRHa) and 24 FtM transgender in total (7 who initiated only GnRHa, 17 who initiated testosterone with or without having taken GnRHa before).
Results : Practice at the CHUV is in line with Gender Dysphoria/Gender Incongruence Guideline. Testosterone treatment significantly increased testosterone level, AMH level, Androstenedione level, DHEA-S level in FtM patients after 12 months of treatment. Testosterone treatment significantly decreased FSH level and SHBG level, in FtM patients after 12 months of treatment.
Conclusion : Practice at the CHUV is in line with Gender Dysphoria/Gender Incongruence Guideline. There seems to be a stimulation of the adrenal gland in FtM patients taking testosterone treatment but further studies are needed with lager cohorts.
Objective : Primary objective is to evaluate adequacy between Gender Dysphoria/Gender Incongruence Guidelines of the Endocrine Society and practice at the CHUV. Secondary objective is to describe anthropometric and hormonal parameters in Female to male (FtM) and Male to Female (MtF) starting GnRHa and in FtM starting testosterone.
Design : Observational, prospective and retrospective study
Intervention(s) : Puberty suppression treatment with GnRHa in FtM and in MtF patients. Gender-affirming hormone therapy (GAHT) with testosterone (associated or not with GnRHa) in FtM.
Patients : 2 MtF (both under only GnRHa) and 24 FtM transgender in total (7 who initiated only GnRHa, 17 who initiated testosterone with or without having taken GnRHa before).
Results : Practice at the CHUV is in line with Gender Dysphoria/Gender Incongruence Guideline. Testosterone treatment significantly increased testosterone level, AMH level, Androstenedione level, DHEA-S level in FtM patients after 12 months of treatment. Testosterone treatment significantly decreased FSH level and SHBG level, in FtM patients after 12 months of treatment.
Conclusion : Practice at the CHUV is in line with Gender Dysphoria/Gender Incongruence Guideline. There seems to be a stimulation of the adrenal gland in FtM patients taking testosterone treatment but further studies are needed with lager cohorts.
PID Serval
serval:BIB_7FE3DF628BF9
Date de création
2024-10-18T12:08:56.507Z
Date de création dans IRIS
2025-05-20T21:30:14Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
Mémoire no 10364 Beharry Bhavisha.pdf
Version du manuscrit
imprimatur
Taille
2.86 MB
Format
Adobe PDF
PID Serval
serval:BIB_7FE3DF628BF9.P001
Somme de contrôle
(MD5):a6d5ee37a767bcfbc2afc8464a4b0797